Literature DB >> 15833595

Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.

Francesco Fornai1, Paola Lenzi, Michela Ferrucci, Gloria Lazzeri, Adolfo Bandettini di Poggio, Gianfranco Natale, Carla L Busceti, Francesca Biagioni, Mario Giusiani, Stefano Ruggieri, Antonio Paparelli.   

Abstract

In recent years several clinical and research findings have demonstrated the involvement of the presynaptic protein alpha-synuclein in a variety of neurodegenerative disorders which are known as synucleinopathies. Although the function of this protein in the physiology of the cell remains unknown, it is evident that both genetic alterations or a mere overexpression of the native molecule produces a degeneration of nigral dopamine-containing neurons leading to movement disorders, as demonstrated in inherited Parkinson's disease. In the present study, we investigated whether widely abused drugs such as methamphetamine and methylenedioxymethamphetamine (ecstasy), which are known to damage the nigrostriatal dopamine pathway of mice, increase the expression of alpha-synuclein within dopamine neurons of the substantia nigra pars compacta. The results of this study demonstrate that nigrostriatal dopamine denervation and occurrence of intracellular inclusions in nigral neurons produced by amphetamine derivatives are related to increased expression of alpha-synuclein within dopamine neurons of the substantia nigra. This lends substance to the hypothesis that increased amounts of native alpha-synuclein may be per se a detrimental factor for the dopamine neurons.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15833595     DOI: 10.1016/j.brainresbull.2005.02.022

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  25 in total

1.  Alpha-synuclein deletion decreases motor impulsivity but does not affect risky decision making in a mouse Gambling Task.

Authors:  Yolanda Peña-Oliver; Sandra Sanchez-Roige; David N Stephens; Tamzin L Ripley
Journal:  Psychopharmacology (Berl)       Date:  2014-01-09       Impact factor: 4.530

Review 2.  Amphetamine toxicities: classical and emerging mechanisms.

Authors:  Bryan K Yamamoto; Anna Moszczynska; Gary A Gudelsky
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 3.  Role of Mitochondria in Methamphetamine-Induced Dopaminergic Neurotoxicity: Involvement in Oxidative Stress, Neuroinflammation, and Pro-apoptosis-A Review.

Authors:  Eun-Joo Shin; Hai-Quyen Tran; Phuong-Tram Nguyen; Ji Hoon Jeong; Seung-Yeol Nah; Choon-Gon Jang; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Neurochem Res       Date:  2017-06-07       Impact factor: 3.996

4.  Chronic Methamphetamine Increases Alpha-Synuclein Protein Levels in the Striatum and Hippocampus but not in the Cortex of Juvenile Mice.

Authors:  B Butler; J Gamble-George; P Prins; A North; J T Clarke; H Khoshbouei
Journal:  J Addict Prev       Date:  2014

Review 5.  Neurotoxins and neurotoxicity mechanisms. An overview.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

6.  Diffusion Kurtosis Imaging Detects Microstructural Changes in a Methamphetamine-Induced Mouse Model of Parkinson's Disease.

Authors:  Anas Arab; Jana Ruda-Kucerova; Alzbeta Minsterova; Eva Drazanova; Nikoletta Szabó; Zenon Starcuk; Irena Rektorova; Amit Khairnar
Journal:  Neurotox Res       Date:  2019-06-18       Impact factor: 3.911

7.  D1 but not D4 dopamine receptors are critical for MDMA-induced neurotoxicity in mice.

Authors:  N Granado; S Ares-Santos; R Moratalla
Journal:  Neurotox Res       Date:  2013-11-21       Impact factor: 3.911

Review 8.  The Role of α-Synuclein in Methamphetamine-Induced Neurotoxicity.

Authors:  Manqing Wu; Hang Su; Min Zhao
Journal:  Neurotox Res       Date:  2021-02-08       Impact factor: 3.911

Review 9.  Methamphetamine toxicity and messengers of death.

Authors:  Irina N Krasnova; Jean Lud Cadet
Journal:  Brain Res Rev       Date:  2009-03-25

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.